BioSpace News Archive

Centene Corporation (NYSE: CNC) announced today that its subsidiary Centurion has received notice from the Delaware Department of Correction of the Department’s intent to award two contracts to Centurion for medical and behavioral health services.

The Vilcek Foundation has issued an open call for applications for the 2021 Vilcek Prizes for Creative Promise in Biomedical Science

A well-known market intelligence company, Infiniti Research, has partnered with several top pharma companies to support their new drug development and launch processes and help implement seamless route-to-market strategies through turnkey solutions.

PulsePoint, a programmatically-powered technology company using real time data to transform healthcare, announced record annual growth of its programmatic health platform, Life by PulsePoint™

Medicomp Systems, the leading provider of clinician-driven, point-of-care solutions that fix EHRs, announced today that the company is canceling its participation in the 2020 HIMSS Global Health Conference & Exhibition, March 9–13, 2020 in Orlando to protect the health and safety of its staff from the growing spread of the novel coronavirus (COVID-19).

Invacare Corporation (NYSE: IVC) announced today the launch of the Invacare® AVIVA™ FX Power Wheelchair, setting a new standard for the front-wheel drive power mobility market.

Sage Therapeutics, Inc. announced that on March 2, 2020, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 4,500 shares of its common stock, and 750 performance restricted stock units to 1 new employee under Sage’s 2016 Inducement Equity Plan.

Nuvo Pharmaceuticals Inc., a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, today announced Dr. Reddy’s Laboratories Inc. has launched its generic version of Vimovo in the United States.

Avivagen Inc., a world leader in natural alternatives to antibiotics with its OxC-beta™ technology, announces its unaudited financial results for the first quarter of 2020.

Hikma Pharmaceuticals PLC, announces that its subsidiary Hikma Pharmaceuticals USA Inc. is voluntarily extending its previously-announced recall of certain lots of Ketorolac Tromethamine Injection USP 30mg/mL, 1mL fill/2mL vials to the medical facility and retail levels.